Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CKAP4 is a potential therapeutic target to overcome resistance to EGFR-TKIs in lung adenocarcinoma.

Genes & genomics - 1 Mar 2025

Song Seongeun, Rhee Sangmyung

Abstract excerpt

BACKGROUND: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are standard treatments for non-small cell lung cancer (NSCLC) patients with EGFR mutations; however, drug resistance limits their efficacy. Cytoskeleton-associated protein 4 (CKAP4) has been linked to cancer progression, but its role in EGFR-TKI resistance remains unclear. OBJECTIVE: This study investigates the clinical relevance...

Read the complete abstract on PubMed

Topics

Humans
Drug Resistance, Neoplasm
Adenocarcinoma of Lung
ErbB Receptors
Protein Kinase Inhibitors
Lung Neoplasms
Cell Line, Tumor

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Cytoskeletal Proteins

Aniline Compounds

Gene Expression Regulation, Neoplastic

Prognosis

Mutation

Acrylamides

Indoles

Pyrimidines

Source

Identifiers

PMID: 39704929
DOI: 10.1007/s13258-024-01606-7

Genes

CKAP4
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CKAP4 is a potential therapeutic target to overcome resistance to EGFR-TKIs in lung adenocarcinoma.PMID 39704929Read ↗

Identification and experimental verification of a novel cisplatin resistance-related lncRNA signature for predicting prognosis and immune response in lung adenocarcinoma.Semantic proximity Read ↗

Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer.Semantic proximity Read ↗

The role and mechanism of CHMP4C in poor prognosis and drug sensitivity of lung adenocarcinomaSemantic proximity Read ↗

Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancerSemantic proximity Read ↗

Bulk RNA analysis identified the characteristics and immunoinvasive patterns of osimertinib resistance in patients with non-small cell lung cancerSemantic proximity Read ↗

Global proteome and phosphoproteome alterations in third generation EGFR TKI resistance reveal drug targets to circumvent resistanceSemantic proximity Read ↗

CKAP2 overexpression correlates with worse overall survival in patients with lung adenocarcinoma.Semantic proximity Read ↗

Comprehensive analysis of AK4 as a potential biomarker and analysis and validation of lung adenocarcinomaSemantic proximity Read ↗

KANK1 regulates paclitaxel resistance in lung adenocarcinoma A549 cellsSemantic proximity Read ↗

Transcriptome Sequencing Reveals Key Pathways and Genes Associated with Cisplatin Resistance in Lung Adenocarcinoma A549 CellsSemantic proximity Read ↗

High expression of NEK2 promotes lung cancer progression and drug resistance and is regulated by mutant EGFR.Semantic proximity Read ↗

A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.